AR073514A1 - Metodos de tratamiento de hiperuricemia y estados de enfermedad asociados - Google Patents
Metodos de tratamiento de hiperuricemia y estados de enfermedad asociadosInfo
- Publication number
- AR073514A1 AR073514A1 ARP090103535A ARP090103535A AR073514A1 AR 073514 A1 AR073514 A1 AR 073514A1 AR P090103535 A ARP090103535 A AR P090103535A AR P090103535 A ARP090103535 A AR P090103535A AR 073514 A1 AR073514 A1 AR 073514A1
- Authority
- AR
- Argentina
- Prior art keywords
- hyperuricemia
- dosage form
- renal
- uric acid
- gout
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 5
- 201000001431 Hyperuricemia Diseases 0.000 title abstract 4
- 201000005569 Gout Diseases 0.000 abstract 4
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 abstract 3
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 abstract 3
- 239000002552 dosage form Substances 0.000 abstract 3
- 229940116269 uric acid Drugs 0.000 abstract 3
- 206010003246 arthritis Diseases 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 229960000367 inositol Drugs 0.000 abstract 2
- 208000009304 Acute Kidney Injury Diseases 0.000 abstract 1
- 208000019838 Blood disease Diseases 0.000 abstract 1
- 208000024172 Cardiovascular disease Diseases 0.000 abstract 1
- 206010018634 Gouty Arthritis Diseases 0.000 abstract 1
- 108700017799 HPRT-Related Gout Proteins 0.000 abstract 1
- 208000027408 HRPT-related hyperuricemia Diseases 0.000 abstract 1
- 206010020772 Hypertension Diseases 0.000 abstract 1
- 208000000913 Kidney Calculi Diseases 0.000 abstract 1
- 208000009625 Lesch-Nyhan syndrome Diseases 0.000 abstract 1
- 208000015924 Lithiasis Diseases 0.000 abstract 1
- 241000124008 Mammalia Species 0.000 abstract 1
- 208000001145 Metabolic Syndrome Diseases 0.000 abstract 1
- 206010029148 Nephrolithiasis Diseases 0.000 abstract 1
- 208000035318 Partial hypoxanthine-guanine phosphoribosyl transferase deficiency Diseases 0.000 abstract 1
- 201000004681 Psoriasis Diseases 0.000 abstract 1
- 208000001647 Renal Insufficiency Diseases 0.000 abstract 1
- 208000033626 Renal failure acute Diseases 0.000 abstract 1
- 208000035317 Total hypoxanthine-guanine phosphoribosyl transferase deficiency Diseases 0.000 abstract 1
- 206010046337 Urate nephropathy Diseases 0.000 abstract 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 abstract 1
- 208000017733 acquired polycythemia vera Diseases 0.000 abstract 1
- 201000011040 acute kidney failure Diseases 0.000 abstract 1
- 208000012998 acute renal failure Diseases 0.000 abstract 1
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 210000000601 blood cell Anatomy 0.000 abstract 1
- 231100001015 blood dyscrasias Toxicity 0.000 abstract 1
- 230000001684 chronic effect Effects 0.000 abstract 1
- 208000029078 coronary artery disease Diseases 0.000 abstract 1
- 230000006378 damage Effects 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 208000002296 eclampsia Diseases 0.000 abstract 1
- 238000013265 extended release Methods 0.000 abstract 1
- 208000014951 hematologic disease Diseases 0.000 abstract 1
- 208000018706 hematopoietic system disease Diseases 0.000 abstract 1
- 239000012729 immediate-release (IR) formulation Substances 0.000 abstract 1
- 208000018937 joint inflammation Diseases 0.000 abstract 1
- 208000017169 kidney disease Diseases 0.000 abstract 1
- 201000006370 kidney failure Diseases 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 208000037244 polycythemia vera Diseases 0.000 abstract 1
- 230000000306 recurrent effect Effects 0.000 abstract 1
- 201000000306 sarcoidosis Diseases 0.000 abstract 1
- 208000024891 symptom Diseases 0.000 abstract 1
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
- 208000008281 urolithiasis Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/04—Drugs for disorders of the urinary system for urolithiasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Rheumatology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Pain & Pain Management (AREA)
- Vascular Medicine (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Obesity (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Dermatology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US9702308P | 2008-09-15 | 2008-09-15 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR073514A1 true AR073514A1 (es) | 2010-11-10 |
Family
ID=41319433
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP090103535A AR073514A1 (es) | 2008-09-15 | 2009-09-15 | Metodos de tratamiento de hiperuricemia y estados de enfermedad asociados |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US8748496B2 (enExample) |
| EP (1) | EP2349280B1 (enExample) |
| JP (1) | JP5685192B2 (enExample) |
| AR (1) | AR073514A1 (enExample) |
| AU (1) | AU2009290612B2 (enExample) |
| CA (1) | CA2737163C (enExample) |
| ES (1) | ES2521674T3 (enExample) |
| TW (1) | TW201016208A (enExample) |
| WO (2) | WO2010031051A1 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7521481B2 (en) * | 2003-02-27 | 2009-04-21 | Mclaurin Joanne | Methods of preventing, treating and diagnosing disorders of protein aggregation |
| KR20080009111A (ko) | 2005-04-11 | 2008-01-24 | 새비언트 파마수티컬즈 인크. | 유레이트 옥시다아제의 변이형 및 이의 용도 |
| AU2010265964B2 (en) | 2009-06-25 | 2014-09-18 | Horizon Therapeutics Usa, Inc. | Methods and kits for predicting infusion reaction risk and antibody-mediated loss of response by monitoring serum uric acid during PEGylated uricase therapy |
| CN102726721A (zh) * | 2011-12-21 | 2012-10-17 | 聂存良 | 一种平衡性的微量元素排铅口服液 |
| US20160303050A1 (en) * | 2015-04-20 | 2016-10-20 | Twi Biotechnology, Inc. | Formulations containing diacerein and methods of lowering blood levels of uric acid using the same |
| CN110234340A (zh) * | 2016-11-11 | 2019-09-13 | 好利恩风湿病制药有限责任公司 | 泼尼松和尿酸酶分子的组合疗法及其用途 |
| US20200237881A1 (en) | 2019-01-30 | 2020-07-30 | Horizon Pharma Rheumatology Llc | Reducing immunogenicity to pegloticase |
| CN109666687B (zh) * | 2018-12-14 | 2020-08-04 | 艾美科健（中国）生物医药有限公司 | 一种生物转化生产鲨肌醇的大肠埃希氏菌工程菌株及其构建方法和应用 |
| US12121566B2 (en) | 2019-01-30 | 2024-10-22 | Horizon Therapeutics Usa, Inc. | Methods for treating gout |
| US12269875B2 (en) | 2023-08-03 | 2025-04-08 | Jeff R. Peterson | Gout flare prevention methods using IL-1BETA blockers |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5998485A (en) * | 1997-06-16 | 1999-12-07 | Cedars-Sinai Medical Center | Method for modulating immune response with inositol |
| EP1824496A4 (en) * | 2004-11-17 | 2008-07-16 | Joanne Mclaurin | COMPOSITIONS OF SCYLLO-INOSITOL DERIVATIVES AND METHOD FOR THE TREATMENT OF PROTEIN AGGREGATION DISORDERS |
| CA2674048A1 (en) * | 2006-12-29 | 2008-07-10 | Normoxys, Inc. | Cyclitols and their derivatives and their therapeutic applications |
-
2009
- 2009-09-15 EP EP09792556.4A patent/EP2349280B1/en active Active
- 2009-09-15 JP JP2011527043A patent/JP5685192B2/ja active Active
- 2009-09-15 TW TW098131051A patent/TW201016208A/zh unknown
- 2009-09-15 AU AU2009290612A patent/AU2009290612B2/en active Active
- 2009-09-15 CA CA2737163A patent/CA2737163C/en active Active
- 2009-09-15 WO PCT/US2009/056985 patent/WO2010031051A1/en not_active Ceased
- 2009-09-15 AR ARP090103535A patent/AR073514A1/es unknown
- 2009-09-15 WO PCT/US2009/057003 patent/WO2010031061A1/en not_active Ceased
- 2009-09-15 ES ES09792556.4T patent/ES2521674T3/es active Active
- 2009-09-15 US US12/560,113 patent/US8748496B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| ES2521674T3 (es) | 2014-11-13 |
| EP2349280B1 (en) | 2014-07-30 |
| JP5685192B2 (ja) | 2015-03-18 |
| US8748496B2 (en) | 2014-06-10 |
| CA2737163A1 (en) | 2010-03-18 |
| EP2349280A1 (en) | 2011-08-03 |
| WO2010031061A1 (en) | 2010-03-18 |
| AU2009290612B2 (en) | 2015-05-14 |
| WO2010031051A1 (en) | 2010-03-18 |
| US20100152305A1 (en) | 2010-06-17 |
| AU2009290612A1 (en) | 2010-03-18 |
| CA2737163C (en) | 2019-03-12 |
| TW201016208A (en) | 2010-05-01 |
| JP2012502914A (ja) | 2012-02-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR073514A1 (es) | Metodos de tratamiento de hiperuricemia y estados de enfermedad asociados | |
| Ejaz et al. | The role of uric acid in acute kidney injury | |
| Harder et al. | Novel oral anticoagulants: clinical pharmacology, indications and practical considerations | |
| Trevisan et al. | TRPA1 receptor stimulation by hydrogen peroxide is critical to trigger hyperalgesia and inflammation in a model of acute gout | |
| AR118108A2 (es) | Formas cristalinas de un inhibidor de tirosina quinasa de bruton | |
| AR059575A1 (es) | Metodo para el tratamiento de enfermedades inflamatorias | |
| CL2007001972A1 (es) | Ester isopropilico del acido 4-[6-(6-metanosulfonil-2-metilpiridin-3-ilamino)-5-metilpirimidin-4-iloxi]piperidin-1-carboxilico, moduladores del metabolismo; composicion farmaceutica; y su uso para tratar trastornos metabolicos. | |
| Elenjickal et al. | Anticoagulation in patients with chronic kidney disease | |
| CL2007001993A1 (es) | Compuestos derivados de pirimidilciclopentanos hidroxilados y metoxilados; procedimiento de preparacion; composicion farmaceutica; y uso del compuesto en el tratamiento de una enfermedad inflamatoria, hiperproliferante, cardiovascular, neurodegenerat | |
| CL2008001966A1 (es) | Composicion de disolucion oral que comprende lamotrigina,en forma de particulas con lamotrigina recubiertas con una capa para enmascarar el sabor y granulos que comprenden un desinfectante y un alcohol de azucar y/o un hidrato de carbono; metodo de preparacion;uso para tratar trastornos del humor y prevencion de ataques. | |
| AR075423A1 (es) | Composicion farmaceutica que comprende un inhibidor de sglt-2, forma farmaceutica, procedimiento para su preparacion, metodos de tratamiento y sus usos | |
| Yin et al. | Probucol for the prevention of cystatin C-based contrast-induced acute kidney injury following primary or urgent angioplasty: a randomized, controlled trial | |
| WO2006105440A3 (en) | Nicotinamide riboside and analogues thereof | |
| SV2011003828A (es) | Anticuerpos monoclonales contra el inhibidor de la via del factor tisular (tfpi) | |
| AR048588A1 (es) | Uso de inhibidores de la fosfodiesterasa de tipo iii (pde iii) para la reduccion del tamano del corazon en mamiferos que padecen insuficiencia cardiaca | |
| JP2012502914A5 (enExample) | ||
| AR065145A1 (es) | Metodo para reducir la inflamacion y el estres en mamiferos | |
| MX2020001342A (es) | Uso de gaboxadol en el tratamiento contra diabetes y afecciones relacionadas. | |
| UY29274A1 (es) | Composicion farmaceutica para tratar la hipertension, que comprende telmisartano e hidroclorotiazida | |
| JP2015522603A5 (enExample) | ||
| CO6531499A2 (es) | Uso de ranolazina para el tratameinto de enfermedades cardiovasculares | |
| Zaman et al. | The efficacy and tolerability of azilsartan in obese insulin-resistant mice with left ventricular pressure overload | |
| PE20091885A1 (es) | Utilizacion de dronedarona para preparar un medicamento para el tratamiento de pacientes con arritmia y que tienen un incremento del nivel de creatinina debido a la administracion de dronedarona | |
| ES2578729T3 (es) | Agente terapéutico para enfermedades relacionadas con el hígado | |
| Mari et al. | Pulmonary Fibrosis and Diabetes Mellitus: Two coins with the same face |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |